分子製药市场－全球产业规模、份额、趋势、机会和预测，依作物来源、技术、应用、最终用户、地区和竞争格局划分，2020-2030年预测

2024年全球分子製药市场规模为25.6亿美元，预计2030年将以8.00%的复合年增长率成长至40.6亿美元。分子製药是指透过基因工程改造植物、动物或微生物，使其成为生产药物蛋白、疫苗和其他重要治疗化合物的生物反应器。市场成长的主要驱动力是消费者对高性价比生物製药产品的需求不断增长，以及基因工程技术的持续进步提高了生产效率和产量。分子製药平台固有的可扩展性和适应性也显着促进了其市场扩张。

主要市场驱动因素

主要市场挑战

主要市场趋势

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球分子製药市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依作物来源分类（玉米、大麦、烟草、红花、稻米、苜蓿）
  • 依技术分类（基因枪、农桿菌侵染、电穿孔、农桿菌介导的基因转殖、其他）
  • 依应用领域（重组抗体、荷尔蒙、疫苗、工业酵素、蛋白质及蛋白质基材料、技术试剂、营养作物来源、其他）
  • 按最终用户（生物技术和製药公司、合约生产组织、其他）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美分子製药市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲分子製药市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太分子製药市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲分子製药市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲分子製药市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购（如有）
• 产品发布（如有）
• 最新进展

第十三章：全球分子製药市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Agrenvec SL
• Diamante SRL
• Leaf Systems International Limited
• Medicago Inc
• Meristem Therapeutics SA
• Moolec Science SA
• ORF Genetics
• Pfizer, Inc.
• ProdiGene Inc
• Protalix Biotherapeutics, Inc.

第十六章：策略建议

第17章调查会社について・免责事项

\

The Global Molecular Pharming Market, valued at USD 2.56 Billion in 2024, is projected to experience a CAGR of 8.00% to reach USD 4.06 Billion by 2030. Molecular pharming involves the genetic engineering of plants, animals, or microorganisms to serve as bioreactors for producing pharmaceutical proteins, vaccines, and other valuable therapeutic compounds. The market's growth is primarily driven by the increasing demand for cost-effective biopharmaceuticals, coupled with continuous advancements in genetic engineering techniques that enhance production efficiency and yield. The inherent scalability and adaptability of molecular pharming platforms also contribute significantly to its expansion.

Key Market Drivers

The Global Molecular Pharming Market is significantly propelled by continuous advancements in genetic engineering technologies. These innovations enable increasingly precise and efficient modification of organisms for pharmaceutical protein production, fostering the development of novel therapeutic compounds and enhancing production yields. For instance, according to Labiotech. eu, September 30, 2025, "CRISPR technology's next wave: Ten companies to watch in 2025", Chroma, a company building an epigenetic editing platform, secured $135 million in Series B funding in 2023, highlighting substantial investment directed towards refining gene-editing capabilities that underpin molecular pharming applications. Such technological progress, including advanced gene-editing tools and synthetic biology techniques, is crucial for overcoming previous limitations in expression levels and product quality, thereby expanding the feasibility and commercial viability of molecular pharming systems across various platforms like plants and microbial hosts.

Key Market Challenges

A significant challenge impeding the growth of the Global Molecular Pharming Market is the complex regulatory landscape and the stringent approval processes governing genetically modified organisms and their derived products, along with concerns regarding potential environmental contamination risks. This intricate web of regulations directly impacts market expansion by extending the time required to bring novel biopharmaceuticals to market and increasing associated development costs.

The extensive testing, data collection, and sequential regulatory hurdles for genetically modified products, including those produced through molecular pharming, contribute to a prolonged and costly approval pathway. According to EFPIA's 2024 Key Data, an average of 12-13 years elapses from the first synthesis of a new active substance until it reaches the market. This extended timeline delays the commercialization of products and the generation of revenue, thereby diminishing the attractiveness of investing in molecular pharming initiatives. The uncertainty and high capital expenditure linked to navigating these demanding regulatory environments make it more difficult for companies to secure funding and allocate resources to the development of pharming-derived therapeutics, consequently hampering overall market growth.

Key Market Trends

The Global Molecular Pharming Market is experiencing a notable shift due to the diversification of its applications into nutraceutical production. This trend highlights the expansion of molecular pharming beyond traditional pharmaceutical proteins into generating high-value compounds for the functional food and dietary supplement industries. The inherent scalability and cost-effectiveness of molecular pharming platforms, particularly plant-based systems, are well-suited for producing vitamins, antioxidants, and other health-promoting substances, addressing a rising consumer demand for natural and bio-enhanced products. According to the Council for Responsible Nutrition, in 2024, 75% of Americans continued to use dietary supplements, demonstrating sustained consumer interest. This consistent demand propels molecular pharming companies to explore new revenue streams.

Key Market Players

• Agrenvec S.L
• Diamante SRL
• Leaf Systems International Limited
• Medicago Inc
• Meristem Therapeutics S.A.
• Moolec Science SA
• ORF Genetics
• Pfizer, Inc.
• ProdiGene Inc
• Protalix Biotherapeutics, Inc.

Report Scope:

In this report, the Global Molecular Pharming Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Molecular Pharming Market, By Crop Source:

• Maize
• Barley
• Tobacco
• Safflower
• Rice
• Alfalfa

Molecular Pharming Market, By Technology:

• Gene Gun
• Agroinfiltration
• Electroporation
• Agrobacterium-Mediated Gene Transfer
• Others

Molecular Pharming Market, By Application:

• Recombinant Antibodies
• Hormones
• Vaccines
• Industrial Enzymes
• Proteins & Protein-Based Materials
• Technical Reagents
• Nutritional Crop Sources
• Others

Molecular Pharming Market, By End User:

• Biotechnology & Pharmaceutical Companies
• Contract Manufacturing Organizations
• Others

Molecular Pharming Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Molecular Pharming Market.

Available Customizations:

Global Molecular Pharming Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Molecular Pharming Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Crop Source (Maize, Barley, Tobacco, Safflower, Rice, Alfalfa)
  • 5.2.2. By Technology (Gene Gun, Agroinfiltration, Electroporation, Agrobacterium-Mediated Gene Transfer, Others)
  • 5.2.3. By Application (Recombinant Antibodies, Hormones, Vaccines, Industrial Enzymes, Proteins & Protein-Based Materials, Technical Reagents, Nutritional Crop Sources, Others)
  • 5.2.4. By End User (Biotechnology & Pharmaceutical Companies, Contract Manufacturing Organizations, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Molecular Pharming Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Crop Source
  • 6.2.2. By Technology
  • 6.2.3. By Application
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Molecular Pharming Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Crop Source
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Molecular Pharming Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Crop Source
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Molecular Pharming Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Crop Source
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe Molecular Pharming Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Crop Source
  • 7.2.2. By Technology
  • 7.2.3. By Application
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Molecular Pharming Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Crop Source
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. France Molecular Pharming Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Crop Source
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Molecular Pharming Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Crop Source
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Molecular Pharming Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Crop Source
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Molecular Pharming Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Crop Source
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia Pacific Molecular Pharming Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Crop Source
  • 8.2.2. By Technology
  • 8.2.3. By Application
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Molecular Pharming Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Crop Source
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. India Molecular Pharming Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Crop Source
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Molecular Pharming Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Crop Source
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Molecular Pharming Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Crop Source
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Molecular Pharming Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Crop Source
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. Middle East & Africa Molecular Pharming Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Crop Source
  • 9.2.2. By Technology
  • 9.2.3. By Application
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Molecular Pharming Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Crop Source
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Molecular Pharming Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Crop Source
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Molecular Pharming Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Crop Source
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. South America Molecular Pharming Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Crop Source
  • 10.2.2. By Technology
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Molecular Pharming Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Crop Source
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Molecular Pharming Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Crop Source
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Molecular Pharming Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Crop Source
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Molecular Pharming Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Agrenvec S.L
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Diamante SRL
• 15.3. Leaf Systems International Limited
• 15.4. Medicago Inc
• 15.5. Meristem Therapeutics S.A.
• 15.6. Moolec Science SA
• 15.7. ORF Genetics
• 15.8. Pfizer, Inc.
• 15.9. ProdiGene Inc
• 15.10. Protalix Biotherapeutics, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer

\